Wilson Therapeutics Progressing Its Copper Modulating Agent To Phase III
Bolstered by positive top-line Phase II trial data, Sweden-based Wilson Therapeutics will independently progress its copper modulating agent and lead asset into Phase III trials next year for the rare genetic condition known as Wilson's Disease.
You may also be interested in...
Rare copper-overload disorder Wilson disease is seeing a surge of interest: one new copper chelator recently garnered a CHMP recommendation, a novel copper modulator has had promising Phase II data, and French biotech Vivet has secured significant funds to pursue a gene therapy approach to the disease.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.